

Inactivated Vaccines Market (Vaccine Type: Viral Vaccine and Bacterial Vaccine; and Method of Inactivation: Solvent Detergent Method, Radiation Method, pH Concentration, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Market Report | 2024-06-21 | 167 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:

Inactivated Vaccines Market - Scope of Report

TMR's report on the global inactivated vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global inactivated vaccines market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inactivated vaccines market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the inactivated vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inactivated vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global inactivated

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inactivated vaccines market.

The report delves into the competitive landscape of the global inactivated vaccines market. Key players operating in the global inactivated vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global inactivated vaccines market profiled in this report.

Key Questions Answered in Global inactivated vaccines Market Report

- What is the sales/revenue generated by inactivated vaccines across all regions during the forecast period?
- What are the opportunities in the global inactivated vaccines market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?

Inactivated Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global inactivated vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global inactivated vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global inactivated vaccines market.

Table of Contents:

1. Preface
 - 1.1. Market Definition and Scope
 - 1.2. Market Segmentation
 - 1.3. Key Research Objectives
 - 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inactivated Vaccines Market
4. Market Overview
 - 4.1. Introduction
 - 4.1.1. Product Definition
 - 4.1.2. Industry Evolution / Developments
 - 4.2. Overview
 - 4.3. Market Dynamics
 - 4.3.1. Drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034
- 5. Key Insights
 - 5.1. Pipeline Analysis
 - 5.2. Key Product/Brand Analysis
 - 5.3. Key Mergers & Acquisitions
 - 5.4. COVID-19 Pandemic Impact on Industry
- 6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type
 - 6.1. Introduction and Definitions
 - 6.2. Key Findings/Developments
 - 6.3. Market Value Forecast, by Vaccine Type, 2020-2034
 - 6.3.1. Viral Vaccine
 - 6.3.2. Bacterial Vaccine
 - 6.4. Market Attractiveness, by Vaccine Type
- 7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation
 - 7.1. Introduction and Definitions
 - 7.2. Key Findings/Developments
 - 7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 7.3.1. Solvent Detergent Method
 - 7.3.2. Radiation Method
 - 7.3.3. pH Concentration
 - 7.3.4. Others (Heat Inactivation, etc.)
 - 7.4. Market Attractiveness, by Method of Inactivation
- 8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration
 - 8.1. Introduction and Definitions
 - 8.2. Key Findings/Developments
 - 8.3. Market Value Forecast, by Route of Administration, 2020-2034
 - 8.3.1. Oral
 - 8.3.2. Subcutaneous
 - 8.3.3. Intravenous
 - 8.4. Market Attractiveness, by Route of Administration
- 9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user
 - 9.1. Introduction and Definitions
 - 9.2. Key Findings/Developments
 - 9.3. Market Value Forecast, by End-user, 2020-2034
 - 9.3.1. Hospitals
 - 9.3.2. Specialty Clinics
 - 9.3.3. Homecare Settings
 - 9.3.4. Others (Research Centers, etc.)
 - 9.4. Market Attractiveness, by End-user
- 10. Global Inactivated Vaccines Market Analysis and Forecast, by Region
 - 10.1. Key Findings
 - 10.2. Market Value Forecast, by Region, 2020-2034
 - 10.2.1. North America
 - 10.2.2. Europe
 - 10.2.3. Asia Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness, by Region
- 11. North America Inactivated Vaccines Market Analysis and Forecast
 - 11.1. Introduction
 - 11.1.1. Key Findings
 - 11.2. Market Value Forecast, by Vaccine Type, 2020-2034
 - 11.2.1. Viral Vaccine
 - 11.2.2. Bacterial Vaccine
 - 11.3. Market Attractiveness, by Vaccine Type
 - 11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 11.4.1. Solvent Detergent Method
 - 11.4.2. Radiation Method
 - 11.4.3. pH Concentration
 - 11.4.4. Others (Heat Inactivation, etc.)
 - 11.5. Market Attractiveness, by Method of Inactivation
 - 11.6. Market Value Forecast, by Route of Administration, 2020-2034
 - 11.6.1. Oral
 - 11.6.2. Subcutaneous
 - 11.6.3. Intravenous
 - 11.7. Market Attractiveness, by Route of Administration
 - 11.8. Market Value Forecast, by End-user, 2020-2034
 - 11.8.1. Hospitals
 - 11.8.2. Specialty Clinics
 - 11.8.3. Homecare Settings
 - 11.8.4. Others (Research Centers, etc.)
 - 11.9. Market Attractiveness, by End-user
 - 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
 - 11.10.1. U.S.
 - 11.10.2. Canada
 - 11.11. Market Attractiveness Analysis
 - 11.11.1. By Vaccine Type
 - 11.11.2. By Method of Inactivation
 - 11.11.3. By Route of Administration
 - 11.11.4. By End-user
 - 11.11.5. By Country
- 12. Europe Inactivated Vaccines Market Analysis and Forecast
 - 12.1. Introduction
 - 12.1.1. Key Findings
 - 12.2. Market Value Forecast, by Vaccine Type, 2020-2034
 - 12.2.1. Viral Vaccine
 - 12.2.2. Bacterial Vaccine
 - 12.3. Market Attractiveness, by Vaccine Type
 - 12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 12.4.1. Solvent Detergent Method
 - 12.4.2. Radiation Method
 - 12.4.3. pH Concentration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.4.4. Others (Heat Inactivation, etc.)
- 12.5. Market Attractiveness, by Method of Inactivation
- 12.6. Market Value Forecast, by Route of Administration, 2020-2034
 - 12.6.1. Oral
 - 12.6.2. Subcutaneous
 - 12.6.3. Intravenous
- 12.7. Market Attractiveness, by Route of Administration
- 12.8. Market Value Forecast, by End-user, 2020-2034
 - 12.8.1. Hospitals
 - 12.8.2. Specialty Clinics
 - 12.8.3. Homecare Settings
 - 12.8.4. Others (Research Centers, etc.)
- 12.9. Market Attractiveness, by End-user
- 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
 - 12.10.1. Germany
 - 12.10.2. U.K.
 - 12.10.3. France
 - 12.10.4. Italy
 - 12.10.5. Spain
 - 12.10.6. Rest of Europe
- 12.11. Market Attractiveness Analysis
 - 12.11.1. By Vaccine Type
 - 12.11.2. By Method of Inactivation
 - 12.11.3. By Route of Administration
 - 12.11.4. By End-user
 - 12.11.5. By Country/Sub-region
- 13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast
 - 13.1. Introduction
 - 13.1.1. Key Findings
 - 13.2. Market Value Forecast, by Vaccine Type, 2020-2034
 - 13.2.1. Viral Vaccine
 - 13.2.2. Bacterial Vaccine
 - 13.3. Market Attractiveness, by Vaccine Type
 - 13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 13.4.1. Solvent Detergent Method
 - 13.4.2. Radiation Method
 - 13.4.3. pH Concentration
 - 13.4.4. Others (Heat Inactivation, etc.)
 - 13.5. Market Attractiveness, by Method of Inactivation
 - 13.6. Market Value Forecast, by Route of Administration, 2020-2034
 - 13.6.1. Oral
 - 13.6.2. Subcutaneous
 - 13.6.3. Intravenous
 - 13.7. Market Attractiveness, by Route of Administration
 - 13.8. Market Value Forecast, by End-user, 2020-2034
 - 13.8.1. Hospitals
 - 13.8.2. Specialty Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.8.3. Homecare Settings
- 13.8.4. Others (Research Centers, etc.)
- 13.9. Market Attractiveness, by End-user
- 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
 - 13.10.1. China
 - 13.10.2. Japan
 - 13.10.3. India
 - 13.10.4. Australia & New Zealand
 - 13.10.5. Rest of Asia Pacific
- 13.11. Market Attractiveness Analysis
 - 13.11.1. By Vaccine Type
 - 13.11.2. By Method of Inactivation
 - 13.11.3. By Route of Administration
 - 13.11.4. By End-user
 - 13.11.5. By Country/Sub-region
- 14. Latin America Inactivated Vaccines Market Analysis and Forecast
 - 14.1. Introduction
 - 14.1.1. Key Findings
 - 14.2. Market Value Forecast, by Vaccine Type, 2020-2034
 - 14.2.1. Viral Vaccine
 - 14.2.2. Bacterial Vaccine
 - 14.3. Market Attractiveness, by Vaccine Type
 - 14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 14.4.1. Solvent Detergent Method
 - 14.4.2. Radiation Method
 - 14.4.3. pH Concentration
 - 14.4.4. Others (Heat Inactivation, etc.)
 - 14.5. Market Attractiveness, by Method of Inactivation
 - 14.6. Market Value Forecast, by Route of Administration, 2020-2034
 - 14.6.1. Oral
 - 14.6.2. Subcutaneous
 - 14.6.3. Intravenous
 - 14.7. Market Attractiveness, by Route of Administration
 - 14.8. Market Value Forecast, by End-user, 2020-2034
 - 14.8.1. Hospitals
 - 14.8.2. Specialty Clinics
 - 14.8.3. Homecare Settings
 - 14.8.4. Others (Research Centers, etc.)
 - 14.9. Market Attractiveness, by End-user
 - 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
 - 14.10.1. Brazil
 - 14.10.2. Mexico
 - 14.10.3. Rest of Latin America
 - 14.11. Market Attractiveness Analysis
 - 14.11.1. By Vaccine Type
 - 14.11.2. By Method of Inactivation
 - 14.11.3. By Route of Administration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region
- 15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast
 - 15.1. Introduction
 - 15.1.1. Key Findings
 - 15.2. Market Value Forecast, by Vaccine Type, 2020-2034
 - 15.2.1. Viral Vaccine
 - 15.2.2. Bacterial Vaccine
 - 15.3. Market Attractiveness, by Vaccine Type
 - 15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
 - 15.4.1. Solvent Detergent Method
 - 15.4.2. Radiation Method
 - 15.4.3. pH Concentration
 - 15.4.4. Others (Heat Inactivation, etc.)
 - 15.5. Market Attractiveness, by Method of Inactivation
 - 15.6. Market Value Forecast, by Route of Administration, 2020-2034
 - 15.6.1. Oral
 - 15.6.2. Subcutaneous
 - 15.6.3. Intravenous
 - 15.7. Market Attractiveness, by Route of Administration
 - 15.8. Market Value Forecast, by End-user, 2020-2034
 - 15.8.1. Hospitals
 - 15.8.2. Specialty Clinics
 - 15.8.3. Homecare Settings
 - 15.8.4. Others (Research Centers, etc.)
 - 15.9. Market Attractiveness, by End-user
 - 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
 - 15.10.1. GCC Countries
 - 15.10.2. South Africa
 - 15.10.3. Rest of Middle East & Africa
 - 15.11. Market Attractiveness Analysis
 - 15.11.1. By Vaccine Type
 - 15.11.2. By Method of Inactivation
 - 15.11.3. By Route of Administration
 - 15.11.4. By End-user
 - 15.11.5. By Country/Sub-region
- 16. Competition Landscape
 - 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
 - 16.2. Market Share Analysis, by Company (2023)
 - 16.3. Company Profiles
 - 16.3.1. GSK plc
 - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.1.2. Product Portfolio
 - 16.3.1.3. Financial Overview
 - 16.3.1.4. SWOT Analysis
 - 16.3.1.5. Strategic Overview
 - 16.3.2. Novartis AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. SWOT Analysis
- 16.3.2.5. Strategic Overview
- 16.3.3. Mylan N.V.
 - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.3.2. Product Portfolio
 - 16.3.3.3. Financial Overview
 - 16.3.3.4. SWOT Analysis
 - 16.3.3.5. Strategic Overview
- 16.3.4. Sanofi S.A.
 - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.4.2. Product Portfolio
 - 16.3.4.3. Financial Overview
 - 16.3.4.4. SWOT Analysis
 - 16.3.4.5. Strategic Overview
- 16.3.5. Boehringer Ingelheim International GmbH
 - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.5.2. Product Portfolio
 - 16.3.5.3. Financial Overview
 - 16.3.5.4. SWOT Analysis
 - 16.3.5.5. Strategic Overview
- 16.3.6. Merck & Co., Inc.
 - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.6.2. Product Portfolio
 - 16.3.6.3. Financial Overview
 - 16.3.6.4. SWOT Analysis
 - 16.3.6.5. Strategic Overview
- 16.3.7. F. Hoffmann-La Roche AG
 - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.7.2. Product Portfolio
 - 16.3.7.3. Financial Overview
 - 16.3.7.4. SWOT Analysis
 - 16.3.7.5. Strategic Overview
- 16.3.8. Bristol-Myers Squibb Company
 - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.8.2. Product Portfolio
 - 16.3.8.3. Financial Overview
 - 16.3.8.4. SWOT Analysis
 - 16.3.8.5. Strategic Overview
- 16.3.9. Bharat Biotech
 - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 16.3.9.2. Product Portfolio
 - 16.3.9.3. Financial Overview
 - 16.3.9.4. SWOT Analysis
 - 16.3.9.5. Strategic Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.3.10. Serum Institute of India

16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.10.2. Product Portfolio

16.3.10.3. Financial Overview

16.3.10.4. SWOT Analysis

16.3.10.5. Strategic Overview

16.3.11. INOVIO Pharmaceuticals, Inc.

16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.11.2. Product Portfolio

16.3.11.3. Financial Overview

16.3.11.4. SWOT Analysis

16.3.11.5. Strategic Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Inactivated Vaccines Market (Vaccine Type: Viral Vaccine and Bacterial Vaccine; and Method of Inactivation: Solvent Detergent Method, Radiation Method, pH Concentration, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Market Report | 2024-06-21 | 167 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-10

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com